Klotho Neurosciences, Inc. (KLTO) - Total Assets
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) holds total assets worth $10.07 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Klotho Neurosciences, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see KLTO market cap overview for the company's overall valuation and market capitalisation.
Klotho Neurosciences, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Klotho Neurosciences, Inc.'s total assets of $10.07 Million consist of 6.4% current assets and 93.6% non-current assets. Review Klotho Neurosciences, Inc. (KLTO) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.30 Million | 93.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Klotho Neurosciences, Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Klotho Neurosciences, Inc.'s current assets represent 6.4% of total assets in 2024, a decrease from 31.2% in 2020.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2024, down from 31.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 93.0% of total assets, an increase from 68.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 93.6% of total assets.
Klotho Neurosciences, Inc. Competitors by Total Assets
Key competitors of Klotho Neurosciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Klotho Neurosciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 83.69 | 0.16 | 0.03 |
| Quick Ratio | 83.69 | 0.16 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.68 Million | $-827.78K | $-1.49 Million |
Klotho Neurosciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Klotho Neurosciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.71 |
| Latest Market Cap to Assets Ratio | 20.59 |
| Asset Growth Rate (YoY) | 12.1% |
| Total Assets | $2.46 Million |
| Market Capitalization | $50.59 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Klotho Neurosciences, Inc.'s assets at a significant premium (20.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Klotho Neurosciences, Inc.'s assets grew by 12.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Klotho Neurosciences, Inc. (2020–2024)
The table below shows the annual total assets of Klotho Neurosciences, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.46 Million | +12.07% |
| 2023-12-31 | $2.19 Million | -13.65% |
| 2022-12-31 | $2.54 Million | +143.83% |
| 2021-12-31 | $1.04 Million | -2.83% |
| 2020-12-31 | $1.07 Million | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more